In a report published Thursday, Morgan Stanley analyst Daniel Brennan reiterated an Underweight rating and $7.20 price target on Affymetrix AFFX.
In the report, Morgan Stanley noted, “With Q4 already pre-announced, focus was on underlying drivers, '14 outlook, and tone. Management remains confident in a growth inflection, with rev guidance above MS/street, though margin outlook disappointing.”
Affymetrix closed on Wednesday at $8.34.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in